---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-135822"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T04:04:17.053608+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics: Interim CFO Wendy DiCicco departs; CEO Samir Patel assumes interim PFO/PAO roles

## Summary
- Wendy DiCicco's consulting agreement terminated on December 6, 2024, ending her role as Interim CFO, PFO, and PAO.
- Samir Patel, Interim CEO, appointed as Interim Principal Financial Officer and Principal Accounting Officer effective December 12, 2024.
- Board initiated search for a new Chief Financial Officer.
- Separation terms for DiCicco are being finalized and will be disclosed in a subsequent filing.

## SEC filing metadata
- accession: 0000950170-24-135822
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024135822/0000950170-24-135822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024135822/aktx-20241206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-135822
- JSON: https://secwatch.observer/filing/0000950170-24-135822.json
- Plain text: https://secwatch.observer/filing/0000950170-24-135822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.